Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANTATA-M: Canagliflozin Monotherapy in T2DM
NCT01081834Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2010
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of canagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Janssen Pharmaceutical. Started Mar 2010; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01081834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01081834.